TYDAL-TIMI 78 is a Phase 2B dose-ranging study of MAR001 in adults with elevated triglycerides and remnant cholesterol. TYDAL Principal Investigators Drs. Michelle O’Donoghue and Nicholas Marston discuss the trial. TYDAL on ClinicalTrials.gov CONTACT US about TYDAL